Inventiva Reports Randomization Of First Patient In China In NATiV3 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Inventiva has announced the randomization of the first patient in China for the NATiV3 Phase III clinical trial, which has triggered a milestone payment of $3 million from CTTQ. This payment enables Inventiva to meet the conditions required to draw the second €25 million tranche of its loan from the European Investment Bank (EIB).
December 20, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inventiva has received a $3 million milestone payment from CTTQ after randomizing the first patient in China for the NATiV3 Phase III trial, which also allows the company to draw a €25 million tranche from the EIB loan.
The randomization of the first patient in China for Inventiva's NATiV3 Phase III trial has led to a direct financial benefit for the company, with a $3 million payment from CTTQ. This event is significant as it also satisfies the conditions for Inventiva to access further funding through a €25 million tranche of the EIB loan. The news is likely to be viewed positively by investors as it reflects progress in the company's clinical trial and strengthens its financial position in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100